Abstract:BACKGROUND:There is little evidence of combining sorafenib with hepatic arterial infusion chemotherapy (HAIC) after transarterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC). It is important to identify that patients with intermediate and advanced HCC are most likely to benefit from this combination therapy. AIM:To investigate the safety and clinical outcomes of sorafenib combined with HAIC with folinic acid, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) after TACE for intermediate and advanced HCC. METHODS:This prospective phase II study enrolled patients with intermediate and advanced HCC who underwent treatment with sorafenib combined with TACE-HAIC. All patients initially received the standard 400 mg dose of sorafenib twice daily before TACE-HAIC. Participants at our institute with intermediate and advanced HCC underwent routine TACE. Then, the catheter used for embolization was kept in place in the hepatic artery, and oxaliplatin was intra-arterially administered for 6 h, followed by 5-FU for 18 h, and folinic acid was intravenously administered for 2 h. The primary endpoints were safety, as evaluated by the Common Terminology and Criteria for Adverse Events version 4.0, and 12-mo progression-free survival (PFS), as analyzed by the Kaplan-Meier method. As secondary endpoints, the objective response rate (ORR) was evaluated by the modified Response Evaluation Criteria for Solid Tumors, and survival time [overall survival (OS)] was analyzed by the Kaplan-Meier method. RESULTS:Sixty-six participants at our institute with intermediate and advanced HCC were enrolled in this prospective study (mean age, 53.3 ± 11.7 years). Approximately 56.1% of participants had Barcelona Clinic Liver Cancer (BCLC) stage C disease, and 43.9% had BCLC stage B disease. The ORR was 42.4%. The disease control rate was 87.9%. The grade 3-4 toxicities consisted of thrombocytopenia (4.5%), neutropenia (3.0%), and elevated aspartate aminotransferase (12.2%). Hand-foot skin reaction was also observed (40.9%). The median PFS was 13.1 mo (13.5 mo in the BCLC stage B participants and 9.4 mo in the BCLC stage C participants). The 6-mo, 12-mo, and 24-mo PFS rates were 75.0%, 54.7%, and 30.0%, respectively. The median OS was 21.8 mo. CONCLUSION:Sorafenib combined with HAIC (FOLFOX) after TACE may be a feasible treatment choice for intermediate and advanced HCC because this treatment met the prespecified endpoint of a 6-mo PFS rate exceeding 50% and had good patient tolerance. Prospective randomized controlled trials are needed to confirm the effect of this combination therapy.

Sorafenib combined with transcatheter arterial infusion versus sorafenib alone for hepatocellular carcinoma with major portal vein carcinoma thrombosis

Transarterial Chemoembolization Combined with Sorafenib for the Treatment of Hepatocellular Carcinoma with Hepatic Vein Tumor Thrombus

Sorafenib with and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Retrospective Analysis

[Clinical Observation of Transcatheter Arterial Chemoembolization Plus Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma with Different Types of Portal Vein Tumor Thrombosis].

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis

Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review

Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study

Adjuvant Transarterial Chemoembolization with Sorafenib for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Surgery: A Phase III, Multicenter, Randomized, Controlled Trial.

Sorafenib Combined with TACE in Advanced Primary Hepatocellular Carcinoma.

Tu1488 - Sorafenib with or without Transarterial Chemoembolization Plus Radiofrequency Ablation for Advanced Recurrent Hepatocellular Carcinoma

Sorafenib Combined with Embolization Plus Hepatic Arterial Infusion Chemotherapy for Inoperable Hepatocellular Carcinoma.

Efficacy and safety analysis of sorafenib in combination with TACE in treatment of hepatocellular carcinoma

Combination of Sorafenib and TACE Inhibits Portal Vein Invasion for Intermediate Stage HCC: a Single Center Retrospective Controlled Study

984P Sorafenib Plus Hepatic Arterial Infusion Chemotherapy Versus Sorafenib Alone for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis (vp3/4): A Randomized Phase II Trial

Efficacy of Transcatheter Arterial Chemoembolization (tace) in Combination with Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma in Chinese Patients

Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma

Irradiation stent with <SUP>125</SUP>I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma

[The Analysis of the Efficacy and Safety of Combined Transarterial Chemoembolization with Sorafenib in Patients with Large Hepatocellular Carcinoma].

Combined Endovascular Brachytherapy, Sorafenib, and Transarterial Chemobolization Therapy for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus.